Ribavirin treatment for chronic hepatitis D: A pilot study

A. Garripoli, V. Di Marco, R. Cozzolongo, C. Costa, A. Smedile, A. Fabiano, F. Bonino, M. Rizzetto, G. Verme, A. Craxi, F. Rosina

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

To assess whether therapy with Ribavirin may affect the course of chronic delta hepatitis, nine Italian patients with this disease received the drug orally at a dosage of 15 mg/kg daily for 16 weeks. At the end of the therapy period, all patients were followed for 12 additional months. Seven patients completed the trial. Two patients were withdrawn: one developed hemolytic anemia, and the other intractable itching. At the end of treatment HD viremia was reduced in one patient, had cleared in another, and was unchanged in the remaining five patients. None of the patients decreased their alanine transferase (ALT) levels by more than 50%. At the doses given in this study. Ribarivin did not show significant antiviral effects in chronic hepatitis D, and was not effective in reducing the biochemical markers of liver inflammation and necrosis.

Original languageEnglish
Pages (from-to)154-157
Number of pages4
JournalLiver
Volume14
Issue number3
Publication statusPublished - 1994

Fingerprint

Chronic Hepatitis D
Ribavirin
Therapeutics
Viremia
Hemolytic Anemia
Pruritus
Transferases
Alanine
Antiviral Agents
Necrosis
Biomarkers
Inflammation

ASJC Scopus subject areas

  • Hepatology

Cite this

Garripoli, A., Di Marco, V., Cozzolongo, R., Costa, C., Smedile, A., Fabiano, A., ... Rosina, F. (1994). Ribavirin treatment for chronic hepatitis D: A pilot study. Liver, 14(3), 154-157.

Ribavirin treatment for chronic hepatitis D : A pilot study. / Garripoli, A.; Di Marco, V.; Cozzolongo, R.; Costa, C.; Smedile, A.; Fabiano, A.; Bonino, F.; Rizzetto, M.; Verme, G.; Craxi, A.; Rosina, F.

In: Liver, Vol. 14, No. 3, 1994, p. 154-157.

Research output: Contribution to journalArticle

Garripoli, A, Di Marco, V, Cozzolongo, R, Costa, C, Smedile, A, Fabiano, A, Bonino, F, Rizzetto, M, Verme, G, Craxi, A & Rosina, F 1994, 'Ribavirin treatment for chronic hepatitis D: A pilot study', Liver, vol. 14, no. 3, pp. 154-157.
Garripoli A, Di Marco V, Cozzolongo R, Costa C, Smedile A, Fabiano A et al. Ribavirin treatment for chronic hepatitis D: A pilot study. Liver. 1994;14(3):154-157.
Garripoli, A. ; Di Marco, V. ; Cozzolongo, R. ; Costa, C. ; Smedile, A. ; Fabiano, A. ; Bonino, F. ; Rizzetto, M. ; Verme, G. ; Craxi, A. ; Rosina, F. / Ribavirin treatment for chronic hepatitis D : A pilot study. In: Liver. 1994 ; Vol. 14, No. 3. pp. 154-157.
@article{e94c34681ba544f1b1b99611fdbfd8b1,
title = "Ribavirin treatment for chronic hepatitis D: A pilot study",
abstract = "To assess whether therapy with Ribavirin may affect the course of chronic delta hepatitis, nine Italian patients with this disease received the drug orally at a dosage of 15 mg/kg daily for 16 weeks. At the end of the therapy period, all patients were followed for 12 additional months. Seven patients completed the trial. Two patients were withdrawn: one developed hemolytic anemia, and the other intractable itching. At the end of treatment HD viremia was reduced in one patient, had cleared in another, and was unchanged in the remaining five patients. None of the patients decreased their alanine transferase (ALT) levels by more than 50{\%}. At the doses given in this study. Ribarivin did not show significant antiviral effects in chronic hepatitis D, and was not effective in reducing the biochemical markers of liver inflammation and necrosis.",
author = "A. Garripoli and {Di Marco}, V. and R. Cozzolongo and C. Costa and A. Smedile and A. Fabiano and F. Bonino and M. Rizzetto and G. Verme and A. Craxi and F. Rosina",
year = "1994",
language = "English",
volume = "14",
pages = "154--157",
journal = "Liver",
issn = "0106-9543",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Ribavirin treatment for chronic hepatitis D

T2 - A pilot study

AU - Garripoli, A.

AU - Di Marco, V.

AU - Cozzolongo, R.

AU - Costa, C.

AU - Smedile, A.

AU - Fabiano, A.

AU - Bonino, F.

AU - Rizzetto, M.

AU - Verme, G.

AU - Craxi, A.

AU - Rosina, F.

PY - 1994

Y1 - 1994

N2 - To assess whether therapy with Ribavirin may affect the course of chronic delta hepatitis, nine Italian patients with this disease received the drug orally at a dosage of 15 mg/kg daily for 16 weeks. At the end of the therapy period, all patients were followed for 12 additional months. Seven patients completed the trial. Two patients were withdrawn: one developed hemolytic anemia, and the other intractable itching. At the end of treatment HD viremia was reduced in one patient, had cleared in another, and was unchanged in the remaining five patients. None of the patients decreased their alanine transferase (ALT) levels by more than 50%. At the doses given in this study. Ribarivin did not show significant antiviral effects in chronic hepatitis D, and was not effective in reducing the biochemical markers of liver inflammation and necrosis.

AB - To assess whether therapy with Ribavirin may affect the course of chronic delta hepatitis, nine Italian patients with this disease received the drug orally at a dosage of 15 mg/kg daily for 16 weeks. At the end of the therapy period, all patients were followed for 12 additional months. Seven patients completed the trial. Two patients were withdrawn: one developed hemolytic anemia, and the other intractable itching. At the end of treatment HD viremia was reduced in one patient, had cleared in another, and was unchanged in the remaining five patients. None of the patients decreased their alanine transferase (ALT) levels by more than 50%. At the doses given in this study. Ribarivin did not show significant antiviral effects in chronic hepatitis D, and was not effective in reducing the biochemical markers of liver inflammation and necrosis.

UR - http://www.scopus.com/inward/record.url?scp=0028279421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028279421&partnerID=8YFLogxK

M3 - Article

C2 - 8078394

AN - SCOPUS:0028279421

VL - 14

SP - 154

EP - 157

JO - Liver

JF - Liver

SN - 0106-9543

IS - 3

ER -